Involvement of hypoxia-inducible transcription factors in polycystic kidney disease
- PMID: 17322369
- PMCID: PMC1864863
- DOI: 10.2353/ajpath.2007.060455
Involvement of hypoxia-inducible transcription factors in polycystic kidney disease
Abstract
In polycystic kidney disease (PKD), erythropoietin (EPO) production and interstitial vascularization are increased compared with other kidney diseases. EPO and several angiogenic factors are controlled by hypoxia-inducible transcription factors (HIFs), which are composed of a constitutive beta-subunit and two alternative alpha-subunits (HIF-1alpha, HIF-2alpha). We hypothesized that cyst expansion may result in pericystic hypoxia and consecutive up-regulation of HIF and thus examined the expression of HIF-alpha and HIF target genes in human PKD and in a rodent PKD model. HIF-1alpha and HIF-2alpha were found to be up-regulated in cyst epithelium and cells of cyst walls, respectively. The distinct expression pattern of the HIF-alpha isoforms closely resembles the respective pattern in normal kidneys under systemic hypoxia. Pimonidazole staining, a marker for tissue hypoxia, confirmed the existence of regional hypoxia in polycystic kidneys. Immunohistochemistry for selected target genes implicated a role for HIF-1alpha in vascular endothelial growth factor and Glut-1 activation and HIF-2alpha in endoglin and EPO stimulation. Polycystin-deficient cells showed physiological, oxygen-dependent HIF-alpha modulation, excluding a direct influence of polycystin deficiency on HIF-alpha regulation. In conclusion, HIF accumulation in human and rat PKD seems to be responsible for increased EPO production and pericystic hypervascularity and may have an impact on progression of PKD.
Figures










Similar articles
-
Expression of hypoxia-inducible factor-1alpha and -2alpha in hypoxic and ischemic rat kidneys.J Am Soc Nephrol. 2002 Jul;13(7):1721-32. doi: 10.1097/01.asn.0000017223.49823.2a. J Am Soc Nephrol. 2002. PMID: 12089367
-
Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.Oncogene. 2000 Nov 16;19(48):5435-43. doi: 10.1038/sj.onc.1203938. Oncogene. 2000. PMID: 11114720
-
Expression of hypoxia-inducible transcription factors in developing human and rat kidneys.Kidney Int. 2006 Jan;69(1):114-22. doi: 10.1038/sj.ki.5000062. Kidney Int. 2006. PMID: 16374431
-
Role of oxygen and the HIF-pathway in polycystic kidney disease.Cell Signal. 2020 May;69:109524. doi: 10.1016/j.cellsig.2020.109524. Epub 2020 Jan 2. Cell Signal. 2020. PMID: 31904413 Review.
-
Hypoxia and the HIF system in kidney disease.J Mol Med (Berl). 2007 Dec;85(12):1325-30. doi: 10.1007/s00109-007-0278-y. Epub 2007 Nov 20. J Mol Med (Berl). 2007. PMID: 18026918 Review.
Cited by
-
Sleep-Disordered Breathing in Patients with Polycystic Liver and Kidney Disease Referred for Transcatheter Arterial Embolization.Clin J Am Soc Nephrol. 2015 Jun 5;10(6):949-56. doi: 10.2215/CJN.06930714. Epub 2015 Mar 30. Clin J Am Soc Nephrol. 2015. PMID: 25825485 Free PMC article.
-
Evolving Strategies in the Treatment of Anaemia in Chronic Kidney Disease: The HIF-Prolyl Hydroxylase Inhibitors.Drugs. 2022 Nov;82(16):1565-1589. doi: 10.1007/s40265-022-01783-3. Epub 2022 Nov 9. Drugs. 2022. PMID: 36350500 Free PMC article. Review.
-
Renal tubular HIF-2α expression requires VHL inactivation and causes fibrosis and cysts.PLoS One. 2012;7(1):e31034. doi: 10.1371/journal.pone.0031034. Epub 2012 Jan 27. PLoS One. 2012. PMID: 22299048 Free PMC article.
-
The suffocating kidney: tubulointerstitial hypoxia in end-stage renal disease.Nat Rev Nephrol. 2010 Nov;6(11):667-78. doi: 10.1038/nrneph.2010.124. Epub 2010 Sep 28. Nat Rev Nephrol. 2010. PMID: 20877304 Review.
-
A bell-shaped pattern of urinary aquaporin-2-bearing extracellular vesicle release in an experimental model of nephronophthisis.Physiol Rep. 2019 May;7(9):e14092. doi: 10.14814/phy2.14092. Physiol Rep. 2019. PMID: 31074077 Free PMC article.
References
-
- Wilson PD. Polycystic kidney disease. N Engl J Med. 2004;350:151–164. - PubMed
-
- Gabow PA. Autosomal dominant polycystic kidney disease. N Engl J Med. 1993;329:332–342. - PubMed
-
- Cowley BD., Jr Recent advances in understanding the pathogenesis of polycystic kidney disease: therapeutic implications. Drugs. 2004;64:1285–1294. - PubMed
-
- Maïz HB, Abderrahim E, Zouaghi K. Anemia and end-stage renal disease in the developing world. Artif Organs. 2002;26:760–764. - PubMed
-
- Abbott KC, Agodoa LY. Polycystic kidney disease at end-stage renal disease in the United States: patient characteristics and survival. Clin Nephrol. 2002;57:208–214. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous